Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:CPRX

Catalyst Pharmaceuticals Q1 2026 Earnings Report

Catalyst Pharmaceuticals logo
$30.86 +1.92 (+6.63%)
Closing price 04:00 PM Eastern
Extended Trading
$31.20 +0.34 (+1.10%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Catalyst Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
$0.64
Beat/Miss
N/A
One Year Ago EPS
N/A

Catalyst Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$148.18 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Catalyst Pharmaceuticals Announcement Details

Quarter
Q1 2026
Date
5/11/2026
Time
After Market Closes
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Catalyst Pharmaceuticals Earnings Headlines

A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum
April 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/look-catalyst-pharmaceuticals-cprx-valuation-010903189.html
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282619/13009/en/catalyst-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may-11-2026.html
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…tc pixel
May 5 at 1:00 AM  |  Paradigm Press (Ad)
Catalyst Pharmaceuticals stock surges on takeover report
April 27, 2026  |  investing.comhttps://www.investing.com/news/stock-market-news/catalyst-pharmaceuticals-stock-surges-on-takeover-report-93CH-4639510
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma
April 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/catalyst-pharmaceuticals-jumps-on-report-of-interest-from-angelini-pharma/ar-AA21Q2tO
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang
April 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4894477-catalyst-pharmaceuticals-favorable-trial-outcome-could-be-a-meaningful-overhang
See More Catalyst Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Catalyst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catalyst Pharmaceuticals and other key companies, straight to your email.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ:CPRX) is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions.

Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio.

Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.

View Catalyst Pharmaceuticals Profile
Earnings Tools